Low-density lipoprotein cholesterol (LDLC), also known as ‘bad cholesterol,’ contributes to plaque buildup in the arteries and causes damage, making it a ‘silent killer’ ...
Dr Jay Edelberg, Head of the PCSK9 Development and Launch Unit at Sanofi discusses the ongoing clinical trial assessing PCSK9 inhibitors for use in patients with high cholesterol, in our ...
Most statin drugs are FDA-approved for children and teens under age 18, but only if they have a genetic condition that cause extremely high levels of LDL (bad) cholesterol. Yet in 2009 ...